Myriad Genetics, Inc. (NASDAQ:MYGN)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group LLC in a research report issued to clients and investors on Thursday. They presently have a $23.00 target price on the stock, up from their previous target price of $21.00. Jefferies Group LLC’s price objective indicates a potential downside of 17.80% from the company’s current price. Jefferies Group also issued estimates for Myriad Genetics’ Q2 2018 earnings at $0.25 EPS, Q4 2018 earnings at $0.31 EPS and Q4 2019 earnings at $0.29 EPS.

Other research analysts have also recently issued research reports about the company. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Monday, July 17th. Barclays PLC reduced their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Piper Jaffray Companies restated a “hold” rating and set a $22.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th. Finally, Cowen and Company restated a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $22.23.

Shares of Myriad Genetics (NASDAQ:MYGN) opened at 27.98 on Thursday. Myriad Genetics has a one year low of $15.15 and a one year high of $28.18. The firm’s 50-day moving average price is $25.12 and its 200 day moving average price is $20.79. The stock has a market cap of $1.91 billion, a P/E ratio of 59.79 and a beta of 0.31.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a return on equity of 9.80% and a net margin of 2.83%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.36 earnings per share. Equities research analysts expect that Myriad Genetics will post $1.08 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/10/myriad-genetics-nasdaqmygn-hold-rating-reaffirmed-at-jefferies-group-llc.html.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock valued at $183,203,000 after buying an additional 9,536,219 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Myriad Genetics by 16.8% in the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock valued at $120,020,000 after buying an additional 897,287 shares in the last quarter. Camber Capital Management LLC raised its stake in shares of Myriad Genetics by 6.5% in the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock valued at $83,040,000 after buying an additional 265,000 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in shares of Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock valued at $59,058,000 after buying an additional 41,432 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Myriad Genetics by 59.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock valued at $50,742,000 after buying an additional 987,966 shares in the last quarter.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.